Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Augnito’s AI comprehends all English accents with 99% accuracy
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Nous-209 has been developed using the Nouscom's viral vector platform
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated
